Published in J Virol on July 25, 2007
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F). J Biol Chem (2008) 1.44
A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics. Virol J (2009) 1.15
Characterization of Nipah virus from outbreaks in Bangladesh, 2008-2010. Emerg Infect Dis (2012) 1.14
Cysteines in the stalk of the nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation. J Virol (2012) 1.08
Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry. PLoS Pathog (2013) 1.08
Envelope protein dynamics in paramyxovirus entry. MBio (2013) 1.03
Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment. J Virol (2012) 1.00
Tyrosine residues in the cytoplasmic domains affect sorting and fusion activity of the Nipah virus glycoproteins in polarized epithelial cells. J Virol (2010) 0.95
Henipavirus receptor usage and tropism. Curr Top Microbiol Immunol (2012) 0.91
Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies. Biochem Soc Trans (2010) 0.91
Nipah virus infection and glycoprotein targeting in endothelial cells. Virol J (2010) 0.89
Detection of receptor-induced glycoprotein conformational changes on enveloped virions by using confocal micro-Raman spectroscopy. J Virol (2013) 0.89
New insights into the Hendra virus attachment and entry process from structures of the virus G glycoprotein and its complex with Ephrin-B2. PLoS One (2012) 0.89
Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation. J Virol (2013) 0.88
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses (2012) 0.87
Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J (2013) 0.86
Nipah virion entry kinetics, composition, and conformational changes determined by enzymatic virus-like particles and new flow virometry tools. J Virol (2014) 0.85
Individual N-glycans added at intervals along the stalk of the Nipah virus G protein prevent fusion but do not block the interaction with the homologous F protein. J Virol (2013) 0.85
Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus. Proc Natl Acad Sci U S A (2015) 0.84
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Rhabdovirus-based vaccine platforms against henipaviruses. J Virol (2014) 0.84
Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail. Virol J (2008) 0.83
Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin Cell Dev Biol (2011) 0.81
Subclinical infection without encephalitis in mice following intranasal exposure to Nipah virus-Malaysia and Nipah virus-Bangladesh. Virol J (2014) 0.81
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. PLoS One (2012) 0.81
Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus. J Virol (2015) 0.80
Attachment protein G of an African bat henipavirus is differentially restricted in chiropteran and nonchiropteran cells. J Virol (2014) 0.79
Henipavirus infections: lessons from animal models. Pathogens (2013) 0.78
Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment. PLoS Pathog (2016) 0.77
Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther (2013) 0.77
Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol (2015) 0.77
Paramyxovirus Glycoproteins and the Membrane Fusion Process. Curr Clin Microbiol Rep (2016) 0.76
Multiple Novel Functions of Henipavirus O-glycans: The First O-glycan Functions Identified in the Paramyxovirus Family. PLoS Pathog (2016) 0.76
Containing the contagion: treating the virus that inspired the film. Sci Transl Med (2011) 0.75
Stimulation of Nipah Fusion: Small Intradomain Changes Trigger Extensive Interdomain Rearrangements. Biophys J (2016) 0.75
A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 44.81
Genome-wide atlas of gene expression in the adult mouse brain. Nature (2006) 28.02
Nipah virus: a recently emergent deadly paramyxovirus. Science (2000) 9.39
A morbillivirus that caused fatal disease in horses and humans. Science (1995) 7.61
Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature (2005) 6.78
Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect (2002) 6.40
Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A (1985) 6.00
Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus. J Gen Virol (2000) 5.87
Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. Emerg Infect Dis (2001) 5.65
Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis (2004) 5.49
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (2005) 4.97
Infection of humans and horses by a newly described morbillivirus. Med J Aust (1995) 4.68
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature (2005) 3.39
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J (2005) 3.14
Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med (2000) 3.12
Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell (2004) 3.11
Nipah virus outbreak in Malaysia. J Clin Virol (2003) 3.00
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis (2006) 2.85
Crystal structure of an Eph receptor-ephrin complex. Nature (2002) 2.80
Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology (2000) 2.63
Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis (2005) 2.62
Isolation and molecular identification of Nipah virus from pigs. Emerg Infect Dis (2004) 2.59
Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol (2001) 2.46
Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology (2006) 2.36
Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol (2002) 2.36
Molecular biology of Hendra and Nipah viruses. Microbes Infect (2001) 2.33
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
Comparative pathology of the diseases caused by Hendra and Nipah viruses. Microbes Infect (2001) 2.21
Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proc Natl Acad Sci U S A (2005) 1.93
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev (2003) 1.86
The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev (2002) 1.80
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
mRNA expression of ephrins and Eph receptor tyrosine kinases in the neonatal and adult mouse central nervous system. J Neurosci Res (2003) 1.53
Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity. J Biol Chem (2006) 1.40
The role of the individual cysteine residues in the formation of the mature, antigenic HN protein of Newcastle disease virus. Virology (1994) 1.28
The attachment protein of Hendra virus has high structural similarity but limited primary sequence homology compared with viruses in the genus Paramyxovirus. Virology (1998) 1.22
Establishment of a Nipah virus rescue system. Proc Natl Acad Sci U S A (2006) 1.20
Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease. AJNR Am J Neuroradiol (2000) 1.11
Ephrins and their receptors: binding versus biology. IUBMB Life (2004) 1.05
Location of, immunogenicity of and relationships between neutralization epitopes on the attachment protein (G) of Hendra virus. J Gen Virol (2005) 0.94
Late clinical and magnetic resonance imaging follow up of Nipah virus infection. J Neurol Neurosurg Psychiatry (2003) 0.94
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature (2005) 3.39
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol (2009) 2.87
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe (2011) 2.25
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood (2009) 2.07
The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis (2005) 2.02
N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol (2006) 1.97
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med (2005) 1.93
Quality of life outcomes in 599 cancer and non-cancer patients with colostomies. J Surg Res (2006) 1.83
Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol (2005) 1.54
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens (2010) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol (2007) 1.48
Novel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokines. J Immunol (2005) 1.47
Revision and psychometric testing of the City of Hope Quality of Life-Ostomy Questionnaire. Qual Life Res (2004) 1.46
A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F). J Biol Chem (2008) 1.44
Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A (2011) 1.40
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog (2010) 1.32
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology (2010) 1.31
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol (2010) 1.23
Galectin-1-matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. J Immunol (2006) 1.17
Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr (2009) 1.17
Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells. Mol Microbiol (2006) 1.16
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol (2003) 1.16
Noninvasive identification of human central sulcus: a comparison of gyral morphology, functional MRI, dipole localization, and direct cortical mapping. Neuroimage (2003) 1.16
A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics. Virol J (2009) 1.15
Indications and use of palliative surgery-results of Society of Surgical Oncology survey. Ann Surg Oncol (2002) 1.14
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Cysteines in the stalk of the nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation. J Virol (2012) 1.08
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res (2002) 1.08
Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry. PLoS Pathog (2013) 1.08
Controllable hydrogen sulfide donors and their activity against myocardial ischemia-reperfusion injury. ACS Chem Biol (2013) 1.07
Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol (2004) 1.07
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
Complications in resident-performed phacoemulsification cataract surgery at New Jersey Medical School. Br J Ophthalmol (2007) 1.06
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J Biol Chem (2004) 1.05
Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol (2007) 1.05
Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol (2013) 1.04
Expression of human immunodeficiency virus (HIV)-binding lectin DC-SIGNR: Consequences for HIV infection and immunity. Hum Pathol (2002) 1.03
Triggering of the newcastle disease virus fusion protein by a chimeric attachment protein that binds to Nipah virus receptors. J Biol Chem (2011) 1.03
Rho GTPase activity modulates paramyxovirus fusion protein-mediated cell-cell fusion. Virology (2006) 1.02
Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol (2004) 1.01
A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade. J Virol (2010) 1.01
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology (2011) 1.00
Fluorescent probes based on nucleophilic substitution-cyclization for hydrogen sulfide detection and bioimaging. Chemistry (2013) 1.00
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
Normal versus high tension glaucoma: a comparison of functional and structural defects. J Glaucoma (2010) 0.99
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm (2004) 0.99
Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg (2006) 0.97
Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol (2010) 0.97
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol (2011) 0.97
Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods (2009) 0.96
N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization. J Virol (2012) 0.96
Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology (2003) 0.96
A mechanistic study of tumor-targeted corrole toxicity. Mol Pharm (2011) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol (2009) 0.93
Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. PLoS One (2013) 0.92
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol (2012) 0.92
Henipavirus receptor usage and tropism. Curr Top Microbiol Immunol (2012) 0.91
Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem (2009) 0.91
Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine (Lond) (2012) 0.90
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Heat shock-mediated thermoprotection of larval locomotion compromised by ubiquitous overexpression of Hsp70 in Drosophila melanogaster. J Neurophysiol (2005) 0.89
Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer (2004) 0.89
Detection of receptor-induced glycoprotein conformational changes on enveloped virions by using confocal micro-Raman spectroscopy. J Virol (2013) 0.89
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology (2013) 0.88
Endothelial galectin-1 binds to specific glycans on nipah virus fusion protein and inhibits maturation, mobility, and function to block syncytia formation. PLoS Pathog (2010) 0.88
Regulation of the nucleocytoplasmic trafficking of viral and cellular proteins by ubiquitin and small ubiquitin-related modifiers. Biol Cell (2011) 0.87
Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles. PLoS One (2012) 0.86
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology (2013) 0.86
Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology (2013) 0.85
Individual N-glycans added at intervals along the stalk of the Nipah virus G protein prevent fusion but do not block the interaction with the homologous F protein. J Virol (2013) 0.85
Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity. J Control Release (2012) 0.84
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol (2012) 0.83